Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

被引：20

作者：

Sidana, Surbhi ^{[1
]}

Ahmed, Nausheen ^{[2
]}

Akhtar, Othman S. ^{[3
]}

Heim, Michael ^{[4
]}

Brazauskas, Ruta ^{[4
,5
]}

Hansen, Doris K. ^{[6
]}

Ferreri, Christopher ^{[7
]}

Freeman, Ciara Louise L. ^{[8
]}

Afrough, Aimaz ^{[9
]}

Anderson, Larry D., Jr. ^{[10
]}

Dhakal, Binod ^{[11
]}

Dhanda, Devender ^{[12
]}

Gowda, Lohith ^{[13
,14
]}

Hashmi, Hamza ^{[15
]}

Harrison, Melanie ^{[16
]}

Kitali, Amani

Mirza, Sayeef ^{[17
]}

Patel, Jinalben ^{[4
]}

Patwardhan, Pallavi ^{[16
]}

Usmani, Saad Z. ^{[18
]}

Patel, Krina K. ^{[19
]}

Ganguly, Siddhartha ^{[20
,21
]}

Pasquini, Marcelo ^{[4
]}

机构：

[1] Stanford Univ, Stanford, CA USA

[2] Univ Kansas, Canc Ctr, Westwood, KS USA

[3] Moffit Canc Ctr, Tampa, FL USA

[4] Med Coll Wisconsin, CIBMTR R Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI USA

[5] Med Coll Wisconsin, Div Biostat, Inst Hlth & Equ, Milwaukee, WI USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA

[9] UT SouthWestern Med Ctr, Dallas, TX USA

[10] UT SouthWestern Med Ctr, Myeloma Waldenstroms & Amyloidosis Program, Hematol Malignancies & Cellular Therapy Program, Simmons Comprehens Canc Ctr, Dallas, TX USA

[11] Med Coll Wisconsin, BMT & Cellular Therapy, Div Hematol & Oncol, Dept Med, Milwaukee, WI USA

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] Yale Canc Ctr, New Haven, CT USA

[14] Yale Sch Med, New Haven, CT USA

[15] Med Univ South Carolina, Charleston, SC USA

[16] Bristol Myers Squibb, Princeton, NJ USA

[17] Yale Sch Med, New Haven, CT USA

[18] Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplant Serv, Dept Med, New York, NY USA

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[20] Houston Methodist Hosp, Houston, TX USA

[21] Neal Canc Ctr, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-181762

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[21] Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Hansen, Doris K.
Sidana, Surbhi
Peres, Lauren C.
Leitzinger, Christelle Colin
Shune, Leyla
Shrewsbury, Alexandria
Gonzalez, Rebecca
Sborov, Douglas W.
Wagner, Charlotte
Dima, Danai
Hashmi, Hamza
Kocoglu, Mehmet H.
Atrash, Shebli
Simmons, Gary
Kalariya, Nilesh
Ferreri, Christopher
Afrough, Aimaz
Kansagra, Ankit
Voorhees, Peter
Baz, Rachid
Khouri, Jack
Alsina, Melissa
McGuirk, Joseph
Locke, Frederick L.
Patel, Krina K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (11) : 2087 - +
[22] Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
Munshi, Nikhil C.
Anderson, Larry D., Jr.
Shah, Nina
Jagannath, Sundar
Berdeja, Jesus G.
Lonial, Sagar
Raje, Noopur S.
Siegel, David Samuel DiCapua
Lin, Yi
Oriol, Albert
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Petrocca, Fabio
Connarn, Jamie
Patel, Payal
Huang, Liping
Campbell, Timothy Brandon
Hege, Kristen
San Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[23] KarMMa Subanalysis: Correlation of Baseline Characteristics with Complete Response (CR) to Idecabtagene vicleucel (Ide-Cel, bb2121), a BCMA-Targeted CAR-T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
Einsele, H.
Shah, N.
Munshi, N.
Berdeja, J.
Jagannath, S.
Finney, O.
Martin, N.
Agarwal, A.
Rowe, E.
Campbell, T. B.
San-Miguel, J.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 248 - 248
[24] Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial
Shah, Nina
Munshi, Nikhil C.
Berdeja, Jesus G.
Jagannath, Sundar
Finney, Olivia
Martin, Nathan
Agarwal, Amit
Rowe, Everton
Campbe, Timothy B.
San-Miguel, Jesus F.
BLOOD, 2021, 138
[25] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
Anderson, Larry D., Jr.
Shah, Nina
Jagannath, Sundar
Berdeja, Jesus G.
Lonial, Sagar
Raje, Noopur
Siegel, David S.
Lin, Yi
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Einsele, Hermann
Goldschmidt, Hartmut
Weisel, Katja
Cavo, Michele
Reece, Donna E.
Rambaldi, Alessandro
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S17 - S18
[26] Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
Ferreri, Christopher J.
Hildebrandt, Michelle A. T.
Hashmi, Hamza
Shune, Leyla O.
McGuirk, Joseph P.
Sborov, Douglas W.
Wagner, Charlotte B.
Kocoglu, M. Hakan
Atrash, Shebli
Voorhees, Peter M.
Khouri, Jack
Dima, Danai
Afrough, Aimaz
Sannareddy, Aishwarya
Simmons, Gary
Davis, James
Kalariya, Nilesh
Peres, Lauren C.
Alsina, Melissa
Locke, Frederick L.
Sidana, Surbhi
Hansen, Doris K.
Patel, Krina
Puglianini, Omar Alexis Castaneda
BLOOD, 2022, 140 : 1856 - 1858
[27] Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
Berdeja, Jesus G.
Raje, Noopur S.
Siegel, David S.
Lin, Yi
Anderson, Larry D., Jr.
Rodriguez-Otero, Paula
Manier, Salomon
Einsele, Hermann
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Sanford, Jill
Wang, Julie
Campbell, Timothy B.
Jagannath, Sundar
BLOOD, 2020, 136
[28] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study
Raje, Noopur S.
Siegel, David S.
Jagannath, Sundar
Lonial, Sagar
Munshi, Nikhil C.
Moreau, Philippe
Goldschmidt, Hartmut
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Huang, Liping
Agarwal, Amit
Wang, Julie
Campbell, Timothy B.
San-Miguel, Jesus F.
Reece, Donna E.
BLOOD, 2020, 136
[29] KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma
Delforge, Michel
Baz, Rachid C.
Cavo, Michele
Callander, Natalie S.
Ghobadi, Armin
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Massaro, Monica
Ding, Li
Patel, Payal
Pittari, Gianfranco
Novick, Steven
Giralt, Sergio A.
Berdeja, Jesus G.
BLOOD, 2020, 136
[30] Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, Paula
Ailawadhi, Sikander
Arnulf, Bertrand
Patel, Krina
Cavo, Michele
Nooka, Ajay K.
Manier, Salomon
Callander, Natalie
Costa, Luciano J.
Vij, Ravi
Bahlis, Nizar J.
Moreau, Philippe
Solomon, Scott R.
Delforge, Michel
Berdeja, Jesus
Truppel-Hartmann, Anna
Yang, Zhihong
Favre-Kontula, Linda
Wu, Fan
Piasecki, Julia
Cook, Mark
Giralt, Sergio
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (11): : 1002 - 1014

← 1 2 3 4 5 →